Gilead licenses thymidylate synthase inhibitor from Glaxo

GILD acquired exclusive worldwide rights to Glaxo's GW1843U89 thymidylate synthase inhibitor, which is in Phase I trials against cancer. GILD will pay an upfront license fee, and Glaxo (GLX; LSE:GLXO)...